Skip to main content

Table 1 Characteristics of the study patients

From: Real-life data on the efficacy and safety of erenumab in the Abruzzo region, central Italy

Characteristics (total patients = 89) 
Female, n (%)78 (87.6)
Age, mean ± SD46.8 ± 11.2
Years of migraine history, mean ± SD28.2 ± 13.3
Baseline MMDs, mean ± SD19.8 ± 8.4
Baseline analgesic days, mean ± SD13.5 ± 10.6
Baseline triptan days, mean ± SD8.7 ± 10.4
Chronic migraine, n (%)84 (94.4)
Aura, n (%)27 (30.3)
Allodynia, n (%)33 (37.1)
Medication overuse, n (%)64 (71.9)
Previous preventive treatment failures, n (%)
 228 (31.5)
 324 (27.0)
 426 (29.2)
 > 411 (12.4)
Botulinum toxin failure, n (%)44 (49.4)
Concurrent oral preventive treatments at baseline, n (%)37 (41.6)
\